Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 516

1.

The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women.

Everett BM, Kurth T, Buring JE, Ridker PM.

J Am Coll Cardiol. 2006 Dec 5;48(11):2235-42. Epub 2006 Nov 13.

2.
3.

Lipid levels and the risk of ischemic stroke in women.

Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM.

Neurology. 2007 Feb 20;68(8):556-62.

4.

Lipid profile components and incident cerebrovascular events versus coronary heart disease; the result of 9 years follow-up in Tehran Lipid and Glucose Study.

Tohidi M, Mohebi R, Cheraghi L, Hajsheikholeslami F, Aref S, Nouri S, Azizi F, Hadaegh F.

Clin Biochem. 2013 Jun;46(9):716-21. doi: 10.1016/j.clinbiochem.2013.03.012. Epub 2013 Mar 24.

PMID:
23531403
5.
6.

Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.

Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS.

JAMA. 2007 Aug 15;298(7):776-85.

PMID:
17699011
7.

Comparative analysis of red cell distribution width and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic population: findings from the 1999-2004 NHANES.

Veeranna V, Zalawadiya SK, Panaich S, Patel KV, Afonso L.

Int J Cardiol. 2013 Oct 15;168(6):5156-61. doi: 10.1016/j.ijcard.2013.07.109. Epub 2013 Sep 7.

PMID:
24016543
8.

Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.

Straczek C, Tafflet M, Barberger-Gateau P, Bertrand M, Dupuy AM, Ducimetière P, Empana JP.

Atherosclerosis. 2011 Feb;214(2):426-31. doi: 10.1016/j.atherosclerosis.2010.10.040. Epub 2010 Nov 3.

PMID:
21129746
9.

Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.

Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):424-30. doi: 10.1161/ATVBAHA.108.181735. Epub 2009 Jan 2.

10.

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators.

Circulation. 2002 Mar 12;105(10):1162-9.

11.

Major lipids, apolipoproteins, and risk of vascular disease.

Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J.

JAMA. 2009 Nov 11;302(18):1993-2000. doi: 10.1001/jama.2009.1619.

12.

Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines.

Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J.

Circulation. 2004 Nov 2;110(18):2824-30. Epub 2004 Oct 18.

13.

Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.

Navarro JF, Mora C, Muros M, García-Idoate G.

Nephron Clin Pract. 2003;95(4):c128-35.

PMID:
14694274
14.

Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.

Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, Tomassini JE, Lowe RS, Tershakovec AM.

J Clin Lipidol. 2013 Jul-Aug;7(4):292-303. doi: 10.1016/j.jacl.2013.03.007. Epub 2013 Apr 3.

PMID:
23890516
15.

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E.

Arch Intern Med. 2005 Nov 28;165(21):2479-84.

PMID:
16314544
16.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
17.
18.

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB.

Circulation. 2005 Nov 29;112(22):3375-83.

19.

Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry.

Koren-Morag N, Tanne D, Graff E, Goldbourt U.

Arch Intern Med. 2002 May 13;162(9):993-9.

PMID:
11996608
20.

A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.

Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.

Chin Med J (Engl). 2004 Feb;117(2):163-7.

PMID:
14975195
Items per page

Supplemental Content

Write to the Help Desk